Childhood cancer treatment takes toll on hearts of survivors

American Heart Association Meeting Report: Abstract: 10400 (Poster 2186 - Hall F, Core 2)

Study Highlights:

  • Childhood cancer survivors have changes in their arteries that may increase their risks of early heart disease and atherosclerosis.
  • Monitoring these patients for heart disease and managing risk factors will be important following cancer treatment.
Embargoed until 8 a.m. CT/ 9 a.m. ET Sunday, Nov. 17, 2013
This news release is featured in an 8 a.m. CT news conference on Sunday, Nov. 17, 2013.

DALLAS, Nov. 17, 2013 — Cancer treatment takes a toll on the hearts of child survivors, according to research presented at the American Heart Association’s Scientific Sessions 2013.

Cancer is the leading cause of disease-related death among U.S. children, but the rate of survival has increased significantly from a 5-year survival rate of 58.1 percent in 1975–77 to 83.1 percent in 2003-09.

“Research has shown childhood cancer survivors face heart and other health problems decades after treatment,” said Donald R. Dengel, Ph.D., study lead author and a kinesiology professor at the University of Minnesota in Minneapolis. “But researchers had not — until now — looked at the heart health effects of childhood cancer treatment while survivors are still children.”

Dengel and colleagues measured artery stiffness, thickness and function in 319 U.S. boys and girls (ages 9-18) who had survived leukemia or cancerous tumors. Participants had survived 5 years or longer since their initial cancer diagnosis. Comparing the survivors to 208 sibling children not diagnosed with cancer, researchers found:

  • Premature heart disease, as demonstrated by a decline in arterial function, was more likely among the children who survived cancer.
  • Childhood leukemia survivors had a 9 percent decrease in arterial health after completing chemotherapy compared to the non-cancer group.

“Given this increased risk, children who survive cancer should make lifestyle changes to lower their cardiovascular risk,” Dengel said. “Healthcare providers who are managing chemotherapy-treated childhood cancer survivors need to monitor cardiovascular risk factors immediately following the completion of their patients’ cancer therapy.”

The children in the study were predominately white, so the findings might not apply to other racial and ethnic groups, Dengel said.

“And because of differences in childhood cancer treatment protocols, we are unable to attribute the changes in vascular structure and function to a specific chemotherapy agent,” he said.

Co-authors are Aaron S. Kelly, Ph.D.; Lei Zhang, Sc.M.; James S. Hodges, Ph.D.; K. Scott Baker, M.D., M.S.; and Julia Steinberger, M.D., M.S. Author disclosures are on the abstract.

The National Institutes of Health, National Center for Research Resources and General Clinical Research Center Program funded the study.

Note: Actual presentation is 3 p.m. CT/4 p.m. ET Sunday, Nov. 17, 2013.

Learn more information about Cardiovascular Conditions of Childhood.

Downloadable video/audio interviews, B-roll, animation and images related to this news release are on the right column of the release link at

http://newsroom.heart.org/news/childhood-cancer-treatment-takes-toll-on-hearts-of-survivors?preview=3dfd4bacd8fe022bda2c37417ec91452.

Video clips with researchers/authors of the studies will be added to the release link after embargo.

For more news from AHA Scientific Sessions 2013 follow us on Twitter @HeartNews #AHA13.

###

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

For Media Inquiries:
AHA News Media in Dallas: (214) 706-1173
AHA News Media Office, Nov. 16-20,
at the Dallas Convention Center: (214) 853-8008
For Public Inquiries: (800) AHA-USA1 (242-8721)

Related Images

Related Video

AHA/ASA Events & Scientific Confs/Meetings Calendar